E-viri
PDF
Recenzirano
Odprti dostop
-
Armstrong, Paul W; Pieske, Burkert; Anstrom, Kevin J; Ezekowitz, Justin; Hernandez, Adrian F; Butler, Javed; Lam, Carolyn S.P; Ponikowski, Piotr; Voors, Adriaan A; Jia, Gang; McNulty, Steven E; Patel, Mahesh J; Roessig, Lothar; Koglin, Joerg; O’Connor, Christopher M
New England journal of medicine/The New England journal of medicine, 05/2020, Letnik: 382, Številka: 20Journal Article
Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical therapy. The incidence of death from cardiovascular causes or first hospitalization for heart failure was lower among patients who received vericiguat.
